Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 5.1% – Here’s What Happened

Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Free Report)’s stock price dropped 5.1% during mid-day trading on Friday . The company traded as low as $15.28 and last traded at $15.24. Approximately 69,653 shares traded hands during trading, a decline of 94% from the average daily volume of 1,171,587 shares. The stock had previously closed at $16.05.

Analyst Upgrades and Downgrades

EWTX has been the subject of a number of research analyst reports. Raymond James Financial initiated coverage on Edgewise Therapeutics in a report on Wednesday, July 30th. They set a “strong-buy” rating and a $46.00 price objective for the company. The Goldman Sachs Group initiated coverage on Edgewise Therapeutics in a report on Thursday, September 25th. They set a “neutral” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on Edgewise Therapeutics from $40.00 to $30.00 and set an “overweight” rating for the company in a report on Tuesday, August 19th. HC Wainwright began coverage on Edgewise Therapeutics in a research note on Monday, June 30th. They issued a “buy” rating and a $42.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Edgewise Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $38.83.

View Our Latest Report on Edgewise Therapeutics

Edgewise Therapeutics Stock Down 5.9%

The firm has a 50 day simple moving average of $14.59 and a two-hundred day simple moving average of $14.49. The stock has a market capitalization of $1.59 billion, a P/E ratio of -9.75 and a beta of 0.28.

Edgewise Therapeutics (NASDAQ:EWTXGet Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.08. On average, research analysts predict that Edgewise Therapeutics, Inc. will post -1.45 earnings per share for the current year.

Insiders Place Their Bets

In other Edgewise Therapeutics news, CEO Kevin Koch sold 7,972 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.39, for a total transaction of $106,745.08. Following the completion of the sale, the chief executive officer directly owned 30,615 shares in the company, valued at $409,934.85. This represents a 20.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Joanne M. Donovan sold 2,862 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.39, for a total transaction of $38,322.18. Following the transaction, the chief marketing officer owned 25,361 shares of the company’s stock, valued at $339,583.79. This trade represents a 10.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,267 shares of company stock valued at $1,677,815 over the last ninety days. Company insiders own 23.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EWTX. Braidwell LP increased its holdings in shares of Edgewise Therapeutics by 111.9% during the second quarter. Braidwell LP now owns 5,210,831 shares of the company’s stock worth $68,314,000 after buying an additional 2,752,023 shares in the last quarter. Bellevue Group AG increased its holdings in shares of Edgewise Therapeutics by 94.3% during the second quarter. Bellevue Group AG now owns 2,775,997 shares of the company’s stock worth $36,393,000 after buying an additional 1,347,068 shares in the last quarter. First Light Asset Management LLC increased its holdings in shares of Edgewise Therapeutics by 137.3% during the first quarter. First Light Asset Management LLC now owns 1,852,290 shares of the company’s stock worth $40,750,000 after buying an additional 1,071,651 shares in the last quarter. Siren L.L.C. increased its holdings in shares of Edgewise Therapeutics by 131.0% during the first quarter. Siren L.L.C. now owns 1,696,444 shares of the company’s stock worth $37,322,000 after buying an additional 962,101 shares in the last quarter. Finally, Cormorant Asset Management LP increased its holdings in shares of Edgewise Therapeutics by 20.4% during the first quarter. Cormorant Asset Management LP now owns 4,101,992 shares of the company’s stock worth $90,244,000 after buying an additional 695,458 shares in the last quarter.

About Edgewise Therapeutics

(Get Free Report)

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

Read More

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.